Tracheal Stents Market
Tracheal Stents Market Analysis By Material (Metal, Plastic, Silicone), By Patient (Adults, Pediatrics), By End User (Hospitals, Ambulatory Surgical Centers), & By Region - Global Market Insights 2023-2033
Analysis of Tracheal Stents Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Tracheal Stents Market Outlook (2023-2033)
The global tracheal stents market is valued at US$ 126 million in 2023 and is forecasted to increase at a high-value CAGR of 8% and reach US$ 272 million by 2033-end.
Tracheobronchial prostheses, commonly known as tracheal stents or airway stents, are tubes having a hollow lumen that is implanted into an airway. They can be used to treat several major airway illnesses and are typically implanted bronchoscopically.
A tracheal stent procedure may help mend or regulate airway fistulas, stop the spread of a tumour into the airway, or support the airway wall against failure or external concentration. Stents can be constructed from a variety of materials, including silicone tracheal stents, metal tracheal stents, and plastic tracheal stents.
Metal tracheal stent sales are expected to increase at a CAGR of 8% from 2022 to 2023. Many patients are currently being treated with tracheal stents as a result of developments in thoracic medicine and technology. Expandable metallic stents with both covered and uncovered ends have been designed, expanding their indications and longevity.
The only suitable metal stents for malignant airway blockage are covered types, which reduce tumour inner growth. The fundamental benefit of metal stents is that they have a larger internal-to-exterior diameter ratio than silicone stents. Although silicone stents need strict bronchoscopy for implantation, they are less expensive and easier to remove. The development of bioabsorbable stents is most likely to be the key to the future of airway stenting.
Furthermore, they come in a range of sizes and shapes. They may be transient or enduring. Airway stent placement is seen in both malignant and benign causes. Regardless of the indication, the thoracic surgeon or interventional pulmonologist must make sure the patient has no surgically treatable airway illness before placing any stents. In some circumstances, stenting may require or displace surgery, particularly if it lengthens the lesion beyond the standard tracheal resection length of 4 cm.
The Montgomery T-tube is a useful tracheal stent that maintains the tracheal mucosa while offering a functional airway. The majority of patients experience symptomatic relief from its use in both benign and malignant tracheal diseases. Montgomery tracheal stents are easy to insert and rarely result in significant complications. With the rising prevalence of benign trachea stenosis, the use of artificial airways and T-tubes is becoming more and more common.
Due to the rising demand for (MIS) minimally-invasive surgeries for the treatment of chronic conditions such as lung cancer, chronic obstructive pulmonary disease, glaucoma, central airway obstruction, breathing problems, etc., the tracheal stents market is anticipated to experience profitable growth over the forecast period. Demand for tracheal stents is expected to increase quickly during the forecast period due to the increasing prevalence of such illnesses brought on by sedentary lifestyles and polluted environments.
Market Size (2023E)
US$ 126 Million
Forecasted Market Value (2033F)
US$ 272 Million
Global Market Growth Rate (2023-2033)
China Market Growth Rate (2023-2033)
Japan Market Growth Rate (2023-2033)
Germany Market Growth Rate (2023-2033)
Key Companies Profiled
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Why are Sales of Tracheal Stents Increasing Rapidly across Regions?
“Growing Demand for Minimally-invasive Surgeries”
A very complicated issue that commonly contributes to acute airway impairment is laryngeal and tracheal stenosis. Tracheal stenosis typically develops as a result of trauma, protracted intubation, or tracheostomy. Laryngeal stenosis, on the other hand, is typically brought on by caustic damage, granulomatous illness, or a congenital anomaly.
The most common therapies for laryngotracheal stenosis include laryngeal microsurgery or laser-assisted excision, endoscopic dilatation, and endoscopic stent implantation. There is no standard treatment for this condition.
laryngeal stents or tracheal stents are used to anchor a surgical reconstruction of the larynx or trachea or prevent the lumen from collapsing. Materials of different sizes and forms, both absorbable and non-absorbable, can be used to create such stents.
As a consequence of advancements in tracheal stents that can provide truthful data on the respiratory tract using innovations such as IoT and data science, the global market for tracheal stents is anticipated to grow rapidly. Globally, there is a greater need for tracheal and laryngeal stents as a result of the rise in emphysema and chronic bronchitis patients.
Patients who undergo minimally-invasive surgeries for respiratory illnesses recover faster, have fewer problems, stay in the hospital for a shorter period, and lose less blood. Demand for these stents is rising due to the quick uptake of bronchoscopy, a minimally-invasive, non-surgical procedure for putting stents.
“Rising Prevalence of Lung Cancer”
The number of people who prefer minimally-invasive procedures for treating breathing problems is rising as a result of numerous advancements in these treatment procedures.
The prevalence of lung cancer has led to a rise in the usage of minimally-invasive techniques. Patients who experience breathing difficulties due to congenital cystic adenomatoid abnormalities choose to have stents implanted. Because of this, the use of airway stents is expanding quickly, which is raising the need for lung stents. Placing a lung stent also costs less and carries a reduced risk of complications than more conventional procedures.
Rising prevalence of such illnesses, which are linked to a sedentary lifestyle and a polluted environment, is boosting the demand for tracheal stents. The airway stent/lung stent market is growing even more quickly due to increasing spending on R&D by both public and private organisations for the development of non-vascular stents.
“High Rate of Chronic Disorders among Senior Generation”
The population rate of senior people across the globe is rising rapidly; the older population is more prone to experience several chronic disorders such as cancer which may be of any type. Also, the immune system lowers with ageing. Therefore, the growing geriatric population along with several chronic diseases is fuelling the sales of tracheal stents.
What May Restrain Tracheal Stent Demand Growth to Some Extent?
“Presence of Alternative Treatment Procedures and High Cost of Tracheal Stent Surgeries”
The accessibility of alternative treatments and the high cost of tracheal stent treatment procedures may impede the growth of the tracheal stent market. Lack of medical experts, particularly in underdeveloped and developing nations, and growing apprehensions regarding the hazards associated with stents are two factors that the manufacturers of tracheal stents are predicted to encounter.
Over the coming years, the respective government's rigorous regulations on product approval and constrained reimbursement practices are anticipated to limit the growth of the tracheal stents market to some extent.
How is Demand for Tracheal Stents Evolving in North America?
“Rapid Advancements in Tracheal Stents and Presence of Key Manufacturers”
North America’s market for tracheal stents is increasing rapidly due to the high prevalence of lung & airway disorders, the advanced healthcare infrastructure, and the reimbursement environment for medical devices such as stents.
- According to the Cancer.Net 2022 update, an estimated 236,740 persons in the United States (117,910 men and 118,830 women) received a lung cancer diagnosis in 2022.
- In addition, 317 new cases of asthma are diagnosed in Canadians every day, according to the Asthma.ca 2021 annual report. Asthma is the third most prevalent chronic illness in Canada, affecting the lives of more than 3.8 million people, according to the same source.
Additionally, there are a lot of research projects being carried out in the region concerning tracheal stents.
- For instance, a custom-fitted 3D stent provides patients with a path to improved breathing, according to the UMMC's 2022 report. According to the concerned research, a 3D-printed silicone stent that fits snugly in the split that separates the left main bronchus from the upper and lower bronchi of the left lung and supplies the patient's lungs with air was implanted in a patient.
The presence of key market players is also boosting sales growth in the region.
- For instance, Alaxo Airway Stents (Alaxo) partnered with Portage College in Alberta, Canada, in March 2021 to increase its footprint in North America.
Demand for tracheal stents in Canada is predicted to rise at a high CAGR of 7.5% during the next 10 years. Furthermore, the overall revenue is rising due to the increase in projects launched by both government and non-government organisations.
- The AACR and ALA celebrate Lung Cancer Awareness Month in November. Through the program, these organizations help raise crucial public knowledge about lung cancer and the value of lung health.
As a result, taking into account the all aforementioned factors, the North American market is predicted to grow significantly during the projection period.
Which Aspects are Supporting the Sales of Tracheal Stents in the European Market?
“Rapidly Growing Medical Tourism”
The Europe market is currently holding a significant share in the global market, Germany and the U.K. are estimated to be leading marketplaces in the European region due to rapid investments in R&D by market players to develop advanced tracheal stents such as reducing chances of tumour growth even after stenting.
Demand for tracheal stents in Germany is expected to progress at a CAGR of 6% during the forecast period. Furthermore, the presence of highly developed healthcare facilities, rapidly growing medical tourism, and rising government initiatives are increasing the sales of tracheal stents in the European region.
Why is Asia Pacific the Fastest-Emerging Market for Tracheal Stents?
“Rapidly Developing Healthcare Systems”
Manufacturing of tracheal stents is being outsourced more rapidly, which is anticipated to propel sales growth in China over the projected year. High R&D expenditures by foreign businesses in the nation also contribute to the increasing demand.
The market for tracheal stents in China is likely to evolve at a CAGR of 12% from 2023 to 2033. Also, factors such as rising lung cancer rates, rapidly ageing population rate, the development of hospitals and clinics, and the accessibility of manpower at affordable production costs all support the market growth in China.
South Korea is one of the top marketplaces in the Asia Pacific region due to its rapidly growing medical systems. In recent years, Korean manufacturers have been creating sophisticated medical devices and evolving in response to end-user needs to achieve maximum productivity. Additionally, these manufacturers are introducing advanced tracheal stents for the successful treatment of target patients, which is predicted to grow the Korean tracheal stents market significantly.
Another nation that is capturing the largest share of the Asia Pacific market throughout the predicted period is Japan. The rapidly rising rate of the senior population and the prevalence of chronic disorders due to increasing sedentary lifestyles are some of the factors increasing the market growth. The sales of tracheal stents in Japan are expected to rise at 5% CAGR during the projected timeframe.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Why are Hospitals the Popular Choice for Treatment Procedures?
“High Intake of Patients Due to Availability of Effective & Advanced Treatment Procedures”
Based on end users, the tracheal stents market is segmented into hospitals, ambulatory surgical centers, and others. Due to the rising number of patients being admitted with chronic illnesses, hospitals hold the highest proportion of the global market.
The number of patient admissions is increasing as a result of hospitals having an abundance of skilled medical personnel. A favourable reimbursement scenario for hospital operations to treat respiratory problems is causing an increase in patients. As there are more public hospitals providing patients with care that is both efficient and economical, the usage of tracheal stents in hospitals is increasing.
More surgeries and bronchoscopies are being performed in hospitals. More people are seeking treatment in hospitals for serious illnesses as respective governments of various nations are offering insurance and financial aid for medical care.
A strong infrastructure also aids in the success of surgical procedures. Hospitals are seeing an increase in demand for tracheal stents as a result of expanding government initiatives aimed at boosting safety and reducing adverse medical events.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
To gain a competitive edge in the market, major companies have used strategies including mergers and acquisitions and strategic alliances. Key players in the tracheal stents market are emphasising the development of cutting-edge products that are more precise and efficient.
- The Massachusetts Institute of Technology developed self-expanding metal stents (SEMS) dubbed HANAROSTENT Esophagus TTS in 2020, and Olympus was the only supplier in the US.
Key Segments of Tracheal Stents Industry Research
By Material :
By Patient :
By End User :
- Ambulatory Surgical Centers
By Region :
- North America
- Latin America
- East Asia
- South Asia & Oceania
- FAQs -
The global tracheal stents market is valued at US$ 126 million in 2023.
Global demand for tracheal stents is expected to increase at a CAGR of 8% from 2023 to 2033.
Worldwide tracheal stent sales are projected to reach US$ 272 million by 2033.
North America and Europe currently hold dominating positions in the global trachea stents market.
Bess Aktiengesellschaft (Bess AG), Boston Scientific Corporation, and Cook Group are key companies in the tracheal stents market.